AELIS
Aelis Farma S.A.
Stock Euronext / Paris – Stock Market Prices, News & Analysis
Aelis Farma S.A. specializes in developing innovative treatments targeting CB1 receptors, notably for cognitive disorders such as schizophrenia.
Aelis Farma S.A.
AELIS
Aelis Farma S.A. specializes in developing innovative treatments targeting CB1 receptors, notably for cognitive disorders such as schizophrenia.
Price history of Aelis Farma S.A.
Price history of Aelis Farma S.A.
Performance & Momentum
Strategic Analysis
Aelis Farma S.A. • 2026
Aelis Farma positions itself as a niche player in French biotech, focused on developing innovative therapeutics targeting CB1 receptors to treat severe cognitive disorders, notably schizophrenia. Its model relies on a specific scientific breakthrough that could address an unmet medical need.
- Focus on an innovative and differentiating pharmacological target
- Potential for a therapeutic breakthrough in a segment with high unmet medical need
- Presence in the French biotech market with recognized expertise
- Very weak past stock performance over the medium and long term
- High inherent risk associated with clinical development stages and dependence on experimental results
The very weak momentum reflects significant pressure on the stock, notably linked to still-uncertain clinical or commercial results. The absence of recent catalysts and the likely financial situation point to a strategy centered on consolidation or the search for partnerships to revive the valuation.
Similar stocks to Aelis Farma S.A.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
